The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
Abstract
Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. By contrast, adaptive licensing (AL) approaches are based on stepwise learning under conditions of acknowledged uncertainty, with iterative phases of data gathering and regulatory evaluation. This approach allows approval to align more closely with patient needs for timely access to new technologies and for data to inform medical decisions. The concept of AL embraces a range of perspectives. Some see AL as an evolutionary step, extending elements that are now in place. Others envision a transformative framework that may require legislative action before implementation. This article summarizes recent AL proposals; discusses how proposals might be translated into practice, with illustrations in different therapeutic areas; and identifies unresolved issues to inform decisions on the design and implementation of AL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,300
Eichler, H.-G., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., Rowland, M., Schneider, C. K., & Bloechl-Daum, B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3501 · Cited by 369
Self-citationDevelopment of Novel Combination Therapies
Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2664 · Cited by 229
Self-citationCoverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’
Tunis, S. R., & Pearson, S. D. (2006) · Health Affairs · doi:10.1377/hlthaff.25.5.1218 · Cited by 210
Equipoise and the Dilemma of Randomized Clinical Trials
Miller, F. G., & Joffe, S. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1011301 · Cited by 189
Drug-Review Deadlines and Safety Problems
Carpenter, D., Zucker, E. J., & Avorn, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0706341 · Cited by 175
Accelerating access to treatments for rare diseases
Dunoyer, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3493 · Cited by 62
Paying for Drug Approvals — Who's Using Whom?
Avorn, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078041 · Cited by 58
Luijn, J. C. F. V., Gribnau, F. W. J., & Leufkens, H. G. M. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02812.x · Cited by 55
Cited by
Larsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K. M., Callréus, T., Rosenzweig, M., & Lip, G. Y. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.020 · Cited by 403
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
When and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
New Japanese initiatives on stem cell therapies
Konomi, K., Tobita, M., Kimura, K., & Sato, D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.03.012 · Cited by 139
Metadata
- Authors
- Eichler, H.-G., Oye, K., Baird, L. G., Abadie, E., Brown, J., L Drum, C., Ferguson, J., Garner, S., Honig, P., Hukkelhoven, M., Lim, J. C. W., Lim, R., Lumpkin, M. M., Neil, G., O'Rourke, B., Pezalla, E., Shoda, D., Seyfert-Margolis, V, Sigal, E. V., Sobotka, J., Tan, D., Unger, T. F., & Hirsch, G.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-02-15
- Volume
- 91
- Issue
- 3
- Pages
- 426-437
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2046426458
- Cited by
- 271
- References
- 17
- FWCI
- 24.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval. https://app.cochat.ai/papers/10.1038/clpt.2011.345
- The paper
- Eichler, H.-G., Oye, K., Baird, L. G., Abadie, E., Brown, J., L Drum, C., Ferguson, J., Garner, S., Honig, P., Hukkelhoven, M., Lim, J. C. W., Lim, R., Lumpkin, M. M., Neil, G., O'Rourke, B., Pezalla, E., Shoda, D., Seyfert-Margolis, V, Sigal, E. V., . . . Hirsch, G. (2012). Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2011.345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.